IAP20 Rec'd PCT/PTO 11 MAY 2006

Practitioner's Docket No. 700953-53666

IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date	
PCT/US2004/037810	12 November 2004 (12.11.2004)	12 November 2003 (12.11.2003)	

TITLE OF INVENTION:

SYSTEM FOR TREATING AND PREVENTING BREAST

CANCER

APPLICANT FOR DO/US:

THERION BIOLOGICS CORPORATION, et al.

CERTIFICATE OF MAILING					
I hereby certify that this correspondence, on the date shown below, is being					
deposited with the United States Postal Service with sufficient postage as Express					
Mail Label No. EV 653005037 US in an envelope addressed to MAIL STOP PCT,					
Commissioner for Patents, P. O. Box 1450, Alexandria, JA 22313-1450.					
Date: May 11, 2006					
Linda M. Ginsberg Name of Person Signing					

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

filed:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References B1 and C1-C6 cited in the attached Forms PTO/SB/08a and b.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being

within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or

(2) within three months of the mailing date of the PCT International

(2) within three months of the mailing date of the PCT International Search Report; or

_	IAP20 Rec'd PCT/PTO 11 MAY 2006
	(3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance , and the requisite Certification or fee under Rule 1.17(p), namely \$180.00, is included herein; or
	(4) after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee , and the requisite Certification, petition, and petition fee are included herein.
<u>X</u>	A copy of the International Search Report is enclosed herewith.
	It is respectfully requested that each of the documents shown on the attached
	form(s) PTO/SB/08a and b be made of record in this application.
	Copies of these documents (CHECK ONE):
X	are enclosed herewith; or
·	have been cited in the parent application, and are thus not being resubmitted herein.
<u>x</u>	Pursuant to 37 C.F.R. §1.98, copies of issued U.S. patents listed on the attached form PTO/SB/08, if any, are no longer required and therefore are not enclosed. These documents can be found in the U.S. PTO issued patents database.

FEE AUTHORIZATION

The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Date: May 11, 2006

Respectfully submitted,

Ronald I. Eisenstein (Reg. No. 30,628)

Leena H. Karttunen (L0207)

NIXON PEABODY LLP

100 Summer Street

Boston, MA 02110-2131

(617) 345-6054

IAP20Rec'd PCT/PTO 11 MAY 2006

					TT MAL YOU
Substitut	e for form 1449A/PTO				Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned		
		I.A. Filing Date	12 November 2004		
		First Named Inventor	Dennis L. Panicali		
		Art Unit	To be assigned		
				Examiner Name	To be assigned
Sheet	1	of	2	Attorney Docket Number	700953-53666

U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.1	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Number - Kind Code ² (if known)	MM-DD-1111	Applicant of Cited Document	1 assages of Activative Figures Appear			
/AW/		110 (527 552	03-27-2003	MINION et al.				
		US-6,537,552						
_/AW/		US-5,827,666	10-27-1998	FINN et al.				
		US-						
		US						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. 1	Foreign Patent Document	Publication Date	Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document				
		Country Code ³ Number ⁴ Kind Code ³ (if known)						
/AW/	B1	WO 98/04727	02-05-1998	Therion Biologics Corp. et al.				
	 							
								
i					<u> </u>			

			
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

IAP20 Rec'd PCT/PTO 11 MAY 2006

Substitute for form 1449A/PTO					Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			ACTIDE	Application Number	To be assigned 4 0 579 0 0
				I.A. Filing Date	12 November 2004
				First Named Inventor	Dennis L. Panicali
			rry)	Art Unit	To be assigned
		Examiner Name	To be assigned		
Sheet	2	of	2	Attorney Docket Number	700953-53666

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AW/	C1	AARTS, Wilhelmina M. et al.; Cancer Research; 62:5770-5777 (October 15, 2002)	
2000000	C2	SCHLOM, Jeffrey et al.; Breast Cancer Research and Treatment; 38:27-39 (1996)	
000000000000000000000000000000000000000	C3	SCHOLL, Susy et al.; Journal of Biomedicine and Biotechnology; 3:194-201 (2003)	
0000	C4	ZAJAC, P. et al.; Human Gene Therapy; 14:1497-1510 (November 1, 2003)	
0000	C5	GREINER et al., Cancer Research, December 2002, vol. 62, 6944-6951	
V	C6	GROSENBACH et al., Cancer Research, June 2001, vol. 61, 4497-4050	

	xaminer	/Anne Marie Wehbe/ (08/26/2009)	Date Considered	08/26/2009
1 2	ignature	/Allife Marie Wellbe/ (00/20/2003)	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.